Aspire BioPharma, Inc. (ASBP) - Net Assets
Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) has net assets worth $3.87 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.12 Million) and total liabilities ($3.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ASBP asset base for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.87 Million |
| % of Total Assets | 54.35% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.32 |
Aspire BioPharma, Inc. - Net Assets Trend (2021–2025)
This chart illustrates how Aspire BioPharma, Inc.'s net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of Aspire BioPharma, Inc. to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Aspire BioPharma, Inc. (2021–2025)
The table below shows the annual net assets of Aspire BioPharma, Inc. from 2021 to 2025. For live valuation and market cap data, see Aspire BioPharma, Inc. stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-6.38 Million | -314.02% |
| 2024-12-31 | $-1.54 Million | -107.87% |
| 2023-12-31 | $19.58 Million | -93.23% |
| 2022-12-31 | $289.07 Million | +60856138.32% |
| 2021-12-31 | $-475.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aspire BioPharma, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2723260600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $353.00 | % |
| Other Components | $20.88 Million | % |
| Total Equity | $-6.38 Million | 100.00% |
Aspire BioPharma, Inc. Competitors by Market Cap
The table below lists competitors of Aspire BioPharma, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Baijiayun Group Ltd
NASDAQ:RTC
|
$7.27 Million |
|
Xcel Brands Inc
NASDAQ:XELB
|
$7.27 Million |
|
BSL Corp Bhd
KLSE:7221
|
$7.27 Million |
|
Cambridge Technology Enterprises Limited
NSE:CTE
|
$7.27 Million |
|
SCC Holdings Bhd
KLSE:0158
|
$7.27 Million |
|
Kaixin Auto Holdings
NASDAQ:KXIN
|
$7.26 Million |
|
Bonk, Inc.
NASDAQ:BNKK
|
$7.26 Million |
|
Asuransi Bina Dana Arta Tbk
JK:ABDA
|
$7.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aspire BioPharma, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,540,088 to -6,376,329, a change of -4,836,241.
- Net loss of 24,480,848 reduced equity.
- New share issuances of 265,827 increased equity.
- Other factors increased equity by 19,378,780.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.48 Million | -383.93% |
| Share Issuances | $265.83K | +4.17% |
| Other Changes | $19.38 Million | +303.92% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Aspire BioPharma, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.00 | $6.52 | x |
| 2022-12-31 | $321.74 | $6.52 | x |
| 2023-12-31 | $40.83 | $6.52 | x |
| 2024-12-31 | $-2.23 | $6.52 | x |
| 2025-12-31 | $-4.27 | $6.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aspire BioPharma, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -394725.06%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (4.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.43K |
| 2022 | 1.16% | 0.00% | 0.00x | 1.04x | $-25.57 Million |
| 2023 | 22.80% | 0.00% | 0.00x | 1.02x | $2.51 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.38 Million |
| 2025 | 0.00% | -394725.06% | 0.00x | 0.00x | $-23.84 Million |
Industry Comparison
This section compares Aspire BioPharma, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,838,508
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aspire BioPharma, Inc. (ASBP) | $3.87 Million | 0.00% | 0.84x | $7.27 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.66 Billion |
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more